Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
100 hedge funds and large institutions have $221M invested in Jounce Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 8 closing their positions.
300% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 8
175% more capital invested
Capital invested by funds: $80.2M → $221M (+$140M)
30% more funds holding
Funds holding: 77 → 100 (+23)
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
4% more call options, than puts
Call options by funds: $876K | Put options by funds: $839K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.71M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$2.56M |
| 3 |
Renaissance Technologies
New York
|
+$1.95M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.69M |
| 2 |
JP Morgan Chase
New York
|
-$1M |
| 3 |
D.E. Shaw & Co
New York
|
-$719K |
| 4 |
Millennium Management
New York
|
-$510K |
| 5 |
SO
STRS Ohio
Columbus,
Ohio
|
-$469K |
JNCE Hedge Fund Activity: Q4 2019 in Review
100 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q4 2019, worth a combined $221M — up 175% from $80.2M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new JNCE positions and 8 closed out — a net gain of 24 holders — while 30 added to existing stakes and 24 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.71M. The largest seller was Wellington Management Group, exiting entirely with an estimated $4.69M sold.
- 100 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q4 2019, up from 77 in Q3 2019.
- Funds reported $221M of Jounce Therapeutics, Inc. Common Stock stock for Q4 2019, up 175% quarter-over-quarter.
- 32 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q4 2019 and 8 closed out, a net change of +24 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q4 2019 was Fidelity Investments, an estimated $2.71M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q4 2019 was Wellington Management Group, an estimated $4.69M sold.
Based on aggregated 13F filings for Q4 2019.